Shares of Merck & Co. Inc. MRK were unchanged Tuesday, on what proved to be an all-around dismal trading session for the ...
An FDA approval of Merck’s drug clesrovimab by June would give physicians another option for protecting newborns from ...
The company is scrapping two drugs aimed at targets called TIGIT and LAG-3, both of which were in the middle of Phase 3 ...
On December 10, JD Health, in collaboration with Merck, a globally renowned biopharmaceutical leader, began offering ...
Shares of Merck & Co. Inc. MRK slipped 1.12% to $100.06 Monday, on what proved to be an all-around mixed trading session for ...
We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going ...
Merck & Co Inc (NYSE:MRK) revealed that it would discontinue the clinical development programs for vibostolimab and ...
Merck has become inexpensive again and combines a good growth outlook with a nice and growing dividend. Learn why MRK stock ...
The US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for clesrovimab (MK-1654), ...
Out with the old, in with the new. The end of the year in biopharma is typically marked by pipeline clear outs, and 2024 is ...
(RTTNews) - Merck & Co Inc. (MRK), Monday said China's National Medical Products Administration (NMPA) has approved Keytruda in combination with chemo therapy as neoadjuvant treatment, then as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback